Elevate Your Investing Strategy:
- Take advantage of TipRanks Premium at 55% off! Unlock powerful investing tools, advanced data, and expert analyst insights to help you invest with confidence.
An announcement from Basilea Pharmaceutica ( (CH:BSLN) ) is now available.
Basilea Pharmaceutica AG announced that it has secured non-dilutive financial support from the Biomedical Advanced Research and Development Authority (BARDA) for the development of its novel oral antibiotic, Ceftibuten-Ledaborbactam Etzadroxil. This funding, which includes an initial USD 6 million and potential additional funding up to USD 153 million, will support the drug’s development for treating complicated urinary tract infections caused by multi-resistant bacteria, enhancing Basilea’s position in the anti-infective market.
The most recent analyst rating on (CH:BSLN) stock is a Buy with a CHF105.00 price target. To see the full list of analyst forecasts on Basilea Pharmaceutica stock, see the CH:BSLN Stock Forecast page.
More about Basilea Pharmaceutica
Basilea Pharmaceutica AG is a Swiss biopharmaceutical company focused on developing and marketing innovative drugs for severe bacterial and fungal infections. The company has successfully launched two hospital-use drugs, Cresemba and Zevtera, and is listed on the Swiss stock exchange.
Average Trading Volume: 45,718
Technical Sentiment Signal: Buy
Current Market Cap: CHF571.9M
See more data about BSLN stock on TipRanks’ Stock Analysis page.